345 related articles for article (PubMed ID: 16234967)
1. Fibroblast growth factor-23 is regulated by 1alpha,25-dihydroxyvitamin D.
Collins MT; Lindsay JR; Jain A; Kelly MH; Cutler CM; Weinstein LS; Liu J; Fedarko NS; Winer KK
J Bone Miner Res; 2005 Nov; 20(11):1944-50. PubMed ID: 16234967
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.
Gutierrez O; Isakova T; Rhee E; Shah A; Holmes J; Collerone G; Jüppner H; Wolf M
J Am Soc Nephrol; 2005 Jul; 16(7):2205-15. PubMed ID: 15917335
[TBL] [Abstract][Full Text] [Related]
4. Treatment of hypocalcemia caused by hypoparathyroidism or pseudohypoparathyroidism with domestic-made calcitriol: a prospective and self-controlled clinical trial.
Wang O; Xing XP; Meng XW; Xia WB; Li M; Jiang Y; Hu YY; Liu HC
Chin Med J (Engl); 2009 Feb; 122(3):279-83. PubMed ID: 19236804
[TBL] [Abstract][Full Text] [Related]
5. Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism.
Nishi H; Nii-Kono T; Nakanishi S; Yamazaki Y; Yamashita T; Fukumoto S; Ikeda K; Fujimori A; Fukagawa M
Nephron Clin Pract; 2005; 101(2):c94-9. PubMed ID: 15956805
[TBL] [Abstract][Full Text] [Related]
6. The relationship between serum intact parathyroid hormone and calcium in idiopathic hypoparathyroidism.
Mizunashi K; Furukawa Y; Abe K; Yoshinaga K
Calcif Tissue Int; 1993 Dec; 53(6):378-83. PubMed ID: 8293350
[TBL] [Abstract][Full Text] [Related]
7. Sporadic hypoparathyroidism treated with teriparatide: a case report and literature review.
Angelopoulos NG; Goula A; Tolis G
Exp Clin Endocrinol Diabetes; 2007 Jan; 115(1):50-4. PubMed ID: 17286236
[TBL] [Abstract][Full Text] [Related]
8. The role of fibroblast growth factor 23 for hypophosphatemia and abnormal regulation of vitamin D metabolism in patients with McCune-Albright syndrome.
Yamamoto T; Imanishi Y; Kinoshita E; Nakagomi Y; Shimizu N; Miyauchi A; Satomura K; Koshiyama H; Inaba M; Nishizawa Y; Jüppner H; Ozono K
J Bone Miner Metab; 2005; 23(3):231-7. PubMed ID: 15838626
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study.
Clarke BL; Kay Berg J; Fox J; Cyran JA; Lagast H
Clin Ther; 2014 May; 36(5):722-36. PubMed ID: 24802860
[TBL] [Abstract][Full Text] [Related]
10. Regulatory mechanisms of circulating fibroblast growth factor 23 in parathyroid diseases.
Imanishi Y; Kobayashi K; Kawata T; Inaba M; Nishizawa Y
Ther Apher Dial; 2007 Oct; 11 Suppl 1():S32-7. PubMed ID: 17976083
[TBL] [Abstract][Full Text] [Related]
11. Parathyroid hormone changes during phosphorus load in patients with chronic renal insufficiency with low serum parathyroid hormone or adynamic bone disease.
Cuppari L; Carvalho AB; Lobão RR; Martini LA; Cendoroglo M; Ventura RT; Draibe SA
Clin Nephrol; 2001 Jul; 56(1):35-43. PubMed ID: 11499657
[TBL] [Abstract][Full Text] [Related]
12. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women.
Burnett SM; Gunawardene SC; Bringhurst FR; Jüppner H; Lee H; Finkelstein JS
J Bone Miner Res; 2006 Aug; 21(8):1187-96. PubMed ID: 16869716
[TBL] [Abstract][Full Text] [Related]
13. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism.
Sato T; Tominaga Y; Ueki T; Goto N; Matsuoka S; Katayama A; Haba T; Uchida K; Nakanishi S; Kazama JJ; Gejyo F; Yamashita T; Fukagawa M
Am J Kidney Dis; 2004 Sep; 44(3):481-7. PubMed ID: 15332221
[TBL] [Abstract][Full Text] [Related]
14. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis.
Shimada T; Hasegawa H; Yamazaki Y; Muto T; Hino R; Takeuchi Y; Fujita T; Nakahara K; Fukumoto S; Yamashita T
J Bone Miner Res; 2004 Mar; 19(3):429-35. PubMed ID: 15040831
[TBL] [Abstract][Full Text] [Related]
15. Effects of active vitamin D3 and parathyroid hormone on the serum osteocalcin in idiopathic hypoparathyroidism and pseudohypoparathyroidism.
Mizunashi K; Furukawa Y; Miura R; Yumita S; Sohn HE; Yoshinaga K
J Clin Invest; 1988 Sep; 82(3):861-5. PubMed ID: 2843573
[TBL] [Abstract][Full Text] [Related]
16. Role of fibroblast growth factor 23 (FGF23) in the metabolism of phosphorus and calcium immediately after kidney transplantation.
Sánchez Fructuoso AI; Maestro ML; Calvo N; De La Orden V; Pérez Flores I; Vidaurreta M; Valero R; Fernández-Pérez C; Barrientos A
Transplant Proc; 2012 Nov; 44(9):2551-4. PubMed ID: 23146451
[TBL] [Abstract][Full Text] [Related]
17. FGF-23 is elevated by chronic hyperphosphatemia.
Gupta A; Winer K; Econs MJ; Marx SJ; Collins MT
J Clin Endocrinol Metab; 2004 Sep; 89(9):4489-92. PubMed ID: 15356053
[TBL] [Abstract][Full Text] [Related]
18. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients.
Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
Nephrol Dial Transplant; 2009 Sep; 24(9):2792-6. PubMed ID: 19395730
[TBL] [Abstract][Full Text] [Related]
19. Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'?
Bhan I; Shah A; Holmes J; Isakova T; Gutierrez O; Burnett SM; Jüppner H; Wolf M
Kidney Int; 2006 Oct; 70(8):1486-94. PubMed ID: 16941023
[TBL] [Abstract][Full Text] [Related]
20. Hypoparathyroidism associated with severe mineral bone disease postrenal transplantation, treated successfully with recombinant PTH.
Mahajan A; Narayanan M; Jaffers G; Concepcion L
Hemodial Int; 2009 Oct; 13(4):547-50. PubMed ID: 19493022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
